2000
DOI: 10.1002/1098-2396(20010101)39:1<95::aid-syn12>3.0.co;2-2
|View full text |Cite
|
Sign up to set email alerts
|

Cholinergic activity of aged rhesus monkeys revealed by positron emission tomography

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

0
10
0

Year Published

2003
2003
2014
2014

Publication Types

Select...
7

Relationship

2
5

Authors

Journals

citations
Cited by 28 publications
(10 citation statements)
references
References 50 publications
0
10
0
Order By: Relevance
“…Rhesus monkeys are considered to serve as a useful model for normal human aging [58] because aged nonhuman primates show many of the age-related behavioral [4,21,37,38] and neurobiological alterations, such as changes in neurons, dendrites and synapses, and in neurotransmitter and brain metabolite concentrations [6,20,37,58,59], that also have been reported in aging humans. Rhesus monkeys in laboratory conditions can reach the age of 35-40 years and may be considered as old when they are between 20 and 25 years.…”
Section: Introductionmentioning
confidence: 99%
“…Rhesus monkeys are considered to serve as a useful model for normal human aging [58] because aged nonhuman primates show many of the age-related behavioral [4,21,37,38] and neurobiological alterations, such as changes in neurons, dendrites and synapses, and in neurotransmitter and brain metabolite concentrations [6,20,37,58,59], that also have been reported in aging humans. Rhesus monkeys in laboratory conditions can reach the age of 35-40 years and may be considered as old when they are between 20 and 25 years.…”
Section: Introductionmentioning
confidence: 99%
“…In addition to mAChR, VAChT‐PET has been expected to be useful for neuropathological research as well as therapeutic drug development for AD. However, only one PET study using (+)‐4[ 18 F]fluorobenzyltrozamicol ((+)‐[ 18 F]FBT) (Efange et al, ) has been reported regarding age‐related changes in VAChT activity in the brain of non‐human primate, showing a reduction in VAChT levels in the monkey brain with increasing age from 10 to 37 years old (Voytko et al, ). However, the same group recently described that, because the poor selectivity of (+)‐[ 18 F]FBT over sigma receptors resulted in unacceptably high nonspecific binding in human subjects, this PET probe was proven not to be clinically useful for imaging VAChT (Tu et al, ).…”
Section: Discussionmentioning
confidence: 99%
“…The higher resolution and the decreased study duration of PET are definite reasons to consider planning future studies with [ 18 F]fluoroethoxybenzovesamicol, ((−)‐[ 18 F]FEOBV), (−)‐( 2R,3R)‐trans ‐2‐hydroxy‐3‐(4‐phenylpiperidino)‐5‐(2‐[ 18 F]fluoroethoxy)‐1,2,3,4‐tetralin (Mulholland et al, 1998), [ 18 F] (+)‐4‐fluorobenzyltrozamicol ((+)‐[ 18 F]FBT) (Voytko et al, 2001), and other PET radioligands for the vesicular ACh transporters.…”
Section: Discussionmentioning
confidence: 99%